GLOSSARY TERM
A “waiver” and pending amendment allowing generic medicines to be made under “compulsory licences” exclusively for export to countries that cannot produce the medicines themselves. The system deals with a problem identified in Paragraph 6 of the 2001 Doha Declaration on the TRIPS (intellectual property) Agreement and Public Health by removing a limit in the TRIPS Agreement’s Article 31(f) on the amount nations can export under a compulsory licence to countries needing the medicines.